![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00660764 |
In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who had not been treated with cholesterol lowering drugs at least in the past three months. Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied.
Condition | Intervention |
---|---|
Hypercholesterolemia Coronary Heart Disease Peripheral Vascular Disease Cerebrovascular Accident Diabetes |
Drug: Rosuvastatin |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS) |
Study Start Date: | May 2003 |
Study Completion Date: | February 2006 |
Primary Completion Date: | April 2005 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
1
Patients eligible for the study were patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C ≥ 3.2 mmol/l. Patients were aged ≥ 18 years and ≤ 70 years (men) and ≤ 75 years (women), according to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. Patient approved to place anonymous results at the disposal of AstraZeneca
|
Drug: Rosuvastatin
Oral
|
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
patients of practices of General Practioners
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | AstraZeneca ( Elisabeth Björk - Medical Science Director ) |
Study ID Numbers: | 25V07 |
Study First Received: | April 15, 2008 |
Last Updated: | April 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00660764 |
Health Authority: | Netherlands: Medical Ethics Review Committee (METC) |
cholesterol coronary heart disease rosuvastatin LDL-C goal |
hypercholesterolemia secondary prevention primary prevention CVA |
Cerebral Infarction Myocardial Ischemia Arteriosclerosis Brain Diseases Cerebrovascular Disorders Rosuvastatin Neoplasm Metastasis Brain Ischemia Hypercholesterolemia Dyslipidemias Arterial Occlusive Diseases Peripheral Vascular Diseases Heart Diseases |
Hyperlipidemias Metabolic Diseases Stroke Diabetes Mellitus Vascular Diseases Central Nervous System Diseases Ischemia Coronary Disease Brain Infarction Infarction Metabolic disorder Coronary Artery Disease Lipid Metabolism Disorders |
Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents Nervous System Diseases |
Enzyme Inhibitors Cardiovascular Diseases Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |